Stockreport

Vigil Neuroscience Reports Third Quarter 2024 Financial Results and Provides Business Update

Vigil Neuroscience, Inc.  (VIGL) 
PDF - Final analysis from IGNITE Phase 2 clinical trial evaluating iluzanebart in ALSP planned for first half of 2025 - - Data from Phase 1 clinical trial evaluating [Read more]